Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential BCMA-CAR-T and CD138-CAR-T therapy for relapsed/refractory multiple myeloma
ChiCTR1900023624Phase 2Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Jun 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BCMA-CAR-T cells and CD138-CAR-T cells in multiple myeloma (MM), sponsored by Henan Provincial People's Hospital. Primary endpoint: PET-CT. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
BCMA-CAR-T cellsCD138-CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900023624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023624.